Enhancement of CAR-T cell-targeted immune responses against solid tumors: role of lowered CARs affinity and addition of PD-1 chimeric antigen complexes

Junyoung Lee; Jason Qin; Shihao Qu; Zhaoyi Li

doi:10.54254/2753-8818/44/20240408

Article Information

Received: 8 September 2023

Published: 26 July 2024

DOI: https://doi.org/10.54254/2753-8818/44/20240408

Article Type: Research Article

Cite this article

Lee,J.;Qin,J.;Qu,S.;Li,Z. (2024). Enhancement of CAR-T cell-targeted immune responses against solid tumors: role of lowered CARs affinity and addition of PD-1 chimeric antigen complexes. Theoretical and Natural Science,44,280-285.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About this Volume

Volume Title: TNS Vol.44

Part of Series: Theoretical and Natural Science

ISSN: 2753-8818 (Print) / 2753-8826 (Online)

Copyright & License

[1]Roy, P. S., Saikia, B. J. (2016). Cancer and cure: A critical analysis. Indian Journal of Cancer, 53(3), 441–442.

[2]Jayaraman, J. et al. (2020). CAR-T design: Elements and their synergistic function. EBioMedicine, 58, 102931.

[3]Liu, X. et al. (2015). Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. Cancer Research, 75(17), 3596–3607.

[4]Michelozzi, L, M. et al. (2020). The enhanced functionality of low-affinity CD19 CAR T-cells is as-sociated with activation priming and a polyfunctional cytokine phenotype. Blood, 136(1), 52-53.

[5]Liu, X. et al. (2016). A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Cancer Research, 76(6), 1578–1590.

[6]Ghorashinan, S. et al. (2019). Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nature medicine, 25(9), 1408–1414.

[7]McCallum, L., Lip, S., & Padmanabhan, S. (2014). Pharmacodynamic Pharmacogenomics. Hand-book of Pharmacogenomics and Stratified Medicine, 365-383.

[8]Johnstone, P. A., Norton, M. S., & Riffenburgh, R. H. (2000). Survival of patients with untreated breast cancer. Journal of Surgical Oncology, 73(4), 273–277.

[9]Yin, X., He, L., & Guo, Z. (2023). T‐cell exhaustion in CAR‐T‐cell therapy and strategies to over-come it. Immunology, 169(4), 400–411.

[10]Spiegel, J. Y. et al. (2021). CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine, 27(8), 1419–1431.

[11]Miliotou, A. N., Papadopoulou, L. C. (2018). Car T-cell Therapy: A New Era in Cancer Immuno-therapy. Current Pharmaceutical Biotechnology, 19(1), 5–18

[12]Ghorashian, S. et al. (2019). Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nature Medicine, 25(9), 1408–1414.

[13]Zhang, J. et al. (2022). Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature, 609(7926), 369–374.